Critical role and therapeutic control of the lectin pathway of complement activation in an abortion-prone mouse mating by Petitbarat, Marie et al.
of February 2, 2017.
This information is current as
an Abortion-Prone Mouse Mating
Lectin Pathway of Complement Activation in 
Critical Role and Therapeutic Control of the
Tedesco
De Simoni, Nathalie Ledee, Gerard Chaouat and Francesco
Bulla, Alessandro Palmioli, Anna Bernardi, Maria-Grazia 
Marie Petitbarat, Paolo Durigutto, Paolo Macor, Roberta
http://www.jimmunol.org/content/195/12/5602
doi: 10.4049/jimmunol.1501361
November 2015;
2015; 195:5602-5607; Prepublished online 11J Immunol 
Material
Supplementary
1.DCSupplemental
http://www.jimmunol.org/content/suppl/2015/11/11/jimmunol.150136
References
http://www.jimmunol.org/content/195/12/5602.full#ref-list-1
, 13 of which you can access for free at: cites 40 articlesThis article 
Subscriptions
http://jimmunol.org/subscriptions
 is online at: The Journal of ImmunologyInformation about subscribing to 
Permissions
http://www.aai.org/ji/copyright.html
Submit copyright permission requests at: 
Email Alerts
http://jimmunol.org/cgi/alerts/etoc
Receive free email-alerts when new articles cite this article. Sign up at: 
Print ISSN: 0022-1767 Online ISSN: 1550-6606. 
Immunologists, Inc. All rights reserved.
Copyright © 2015 by The American Association of
9650 Rockville Pike, Bethesda, MD 20814-3994.
The American Association of Immunologists, Inc.,
 is published twice each month byThe Journal of Immunology
 by guest on February 2, 2017
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
 by guest on February 2, 2017
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
 by guest on February 2, 2017
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
 by guest on February 2, 2017
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
The Journal of Immunology
Critical Role and Therapeutic Control of the Lectin Pathway
of Complement Activation in an Abortion-Prone Mouse
Mating
Marie Petitbarat,*,1 Paolo Durigutto,†,1 Paolo Macor,† Roberta Bulla,† Alessandro Palmioli,‡
Anna Bernardi,‡ Maria-Grazia De Simoni,x Nathalie Ledee,* Gerard Chaouat,{ and
Francesco Tedesco‖
The abortion-prone mating combination CBA/J 3 DBA/2 has been recognized as a model of preeclampsia, and complement
activation has been implicated in the high rate of pregnancy loss observed in CBA/J mice. We have analyzed the implantation sites
collected from DBA/2-mated CBA/J mice for the deposition of the complement recognition molecules using CBA/J mated with
BALB/c mice as a control group. MBL-Awas observed in the implantation sites of CBA/J 3 DBA/2 combination in the absence of
MBL-C and was undetectable in BALB/c-mated CBA/J mice. Conversely, C1q was present in both mating combinations. Search-
ing for other complement components localized at the implantation sites of CBA/J 3 DBA/2, we found C4 and C3, but we failed to
reveal C1r. These data suggest that complement is activated through the lectin pathway and proceeds to completion of the
activation sequence as revealed by C9 deposition. MBL-A was detected as early as 3.5 d of pregnancy, and MBL-A deficiency
prevented pregnancy loss in the abortion-prone mating combination. The contribution of the terminal complex to miscarriage was
supported by the finding that pregnancy failure was largely inhibited by the administration of neutralizing Ab to C5. Treatment of
DBA/2-mated CBA/J mice with Polyman2 that binds to MBL-A with high affinity proved to be highly effective in controlling the
activation of the lectin pathway and in preventing fetal loss. The Journal of Immunology, 2015, 195: 5602–5607.
E
mbryo implantation represents a real challenge for the
maternal immune system, which is continuously con-
fronted during pregnancy with paternal and sex-specific
alloantigens expressed on trophoblasts invading the maternal
decidua, as well as with deported fetal and placental cells. This is
a unique physiologic condition, which requires adaptation of the
immune system to avoid harming the fetoplacental unit and to
ensure regular progression of pregnancy. The adaptive and the
innate arms of the immune system are both involved in this
process and develop strategies to establish a protective envi-
ronment in maternal decidua to prevent fetal demise (1). C is a
humoral component of innate immunity, which fulfills protective
functions providing a critical defense barrier against infectious
agents potentially harmful to the fetus (2, 3). More recent findings
have also disclosed the important role of C in placental develop-
ment in normal pregnancy by promoting tissue remodeling and
vascular changes (4). Besides external Ags, an inflammatory state
that develops post coitum in the preimplantation phase and during
embryo implantation as a result of trophoblast invasion into ma-
ternal decidua contributes to activate the C system. This process
does not occur in any other tissue or organ under physiologic
conditions and leads to the release of activation products that may
damage the developing fetus if they were not controlled by C
regulatory proteins that are widely distributed in the fetoplacental
unit. Unrestrictive C activation may overcome the protective effect
of the C regulatory proteins, causing adverse pregnancy outcomes.
Preeclampsia (PE) is one of the pathologic pregnancies in which
C has been implicated as part of the systemic and local inflammation
associated with this disorder (5). This syndrome that affects 3–5%
of pregnancies is an important cause of maternal and perinatal
morbidity and mortality, and is characterized by hypertension and
proteinuria (6). The idea that C is involved in the development of
PE is based on the finding of C activation products in the circu-
lation and in the detection of C deposits in the placentae of these
patients. However, the direct contribution of C to the pathogenesis
of PE is difficult to establish because PE is a multifactorial clinical
condition that manifests with different clinical features suggesting
the involvement of various pathogenic factors.
Major progress in our understanding of the role of C in PE has
been made using the abortion-prone mating combination CBA/J
female 3 DBA/2 male, characterized by high fetal resorption
rate and growth restriction (7, 8). Girardi and colleagues (9) first
reported their finding that the angiogenic factors are dysregulated
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in CBA/J3 DBA/2 mating with increased levels of soluble vascular-
endothelial growth factor receptor and reduced concentration of
vascular-endothelial growth factor resulting in defective vasculari-
zation and impaired development of the placenta. Subsequently, the
same group showed that CBA/J females mated with DBA/2 males
share with human PE not only elevated levels of antiangiogenic
factors and placental dysfunction, but also proteinuria and glo-
merular endotheliosis, whereas they failed to detect hypertension, a
clinical feature of human PE (10). C has been shown to contribute
to the dysregulation of the angiogenic factors resulting in fetal loss
and intrauterine growth restriction as documented by C3 deposition
at embryo implantation sites and the ability of C inhibitors acting at
C3 and C5a levels to prevent embryo damage, as well proteinuria
and renal pathologic features of PE in CBA/J 3 DBA/2 matings
(9, 11). Interestingly, Girardi and her group (12) have also shown
that C1q-deficient mice present all the features of PE, including
hypertension.
We now present data suggesting that C activation occurs in the
early phase of embryo implantation and triggers the complex series
of events leading to miscarriage in the Ab-independent model of
pregnancy loss observed in CBA/J 3 DBA/2 mating. In addition,
we provide evidence that C is activated through the lectin pathway
and that selective inhibition of the pathway rescues pregnancies in
this mating combination.
Materials and Methods
Polymers and recombinant Abs
Polyman2 is a tetravalent pseudotrimannoside Dendron, known also as
Dendron 12, which is formed by a tetravalent polyester scaffold, decorated
with a mimic of linear 1,2- to 1,6-trimannoside (13), and was previously
shown to bind MBL with high affinity (14).
The neutralizing anti-C5 recombinant Ab that recognizes an epitope
located in the cleavage site of the C5 convertases on the a-chain of human
C5 shared by rat, mouse, and rabbit C5 (15) was produced from a human
single-chain fragment variable fused with hinge-CH2-CH3 regions of
IgG1, as previously described (16). This recombinant Ab was previously
found to prevent C5 activation in several animal models developed in mice
(17, 18) and rats (16, 19–21). An essentially similar procedure was fol-
lowed for the production of a recombinant Ab to human CD20 reported in
a previous publication (22) and used in this study as an unrelated Ab.
Anti-C5 and control recombinant Abs were purified from cell-
conditioned medium loaded on Protein A column and eluted with 1M
NaCl in PBS. Fractions containing the recombinant molecules were se-
lected by ELISA and checked for purity by NaDodSO4-PAGE.
DNA extraction
DNA was extracted from mice tails (CBA/J 3 knockout (KO) C57BL/6)
using spin columns of a commercial DNA extraction kit (NucleoSpin
Tissue, Macherey-Nagel, Germany) according to the manufacturer’s in-
structions. In brief, tails were incubated at 56˚C overnight with lysis buffer
solution and proteinase K. Lysis buffer was then added to the solution and
the samples were further incubated at 70˚C for 10 min. After adding
ethanol, the samples were applied to the column and centrifuged. DNAwas
eluted in water and used for the PCR test.
Polymerase chain reaction
PCRs were performed using 0.5 mg/ml DNA, 0.5 mg/ml of each primer,
Taq polymerase (0.8 U per 50 ml reaction), and a mix containing 103
buffer, 200 mm dNTP, DMSO, and 1.5 mM MgCl2. The amplification
conditions include 1 denaturation cycle (95˚C, 2 min), 40 amplification
cycles (95˚C, 20 s; 60˚C, 20 s; 68˚C, 45 s), and a final extension cycle (68˚C,
5 min). The following primers were used:
MBL-C: left primer, 59-AGGAGAAAAGGGAGAACCA-39, right primer:
59-CCTGGGGGTCCTGTAGGT-39.
MBL-A: left primer, 59-GCTCCTTTACTCTAAAGAAACCCTAGT-39,
right primer: 59-TCACCACACACAGAAGGACAG-39.
The PCR products were analyzed on 10% polyacrylamide gel to identify the
MBL-A KO mice.
Mice
Genetically certified CBA/J females and DBA/2 and BALB/c male mice
were all obtained from Charles River/Iffa Credo (l’Arbresles, France) at the
age of 6–8 wk. The mice were housed in the animal facilities of either
Clamart, Institut National de la Recherche Agronomique Jouy en Josas, or
center Hayem/Hoˆpital St. Louis (Paris, France) for 15 d and in the case of
6-wk-old mice for 30 d before mating.
Generation of CBA/J MBL-A null mice
Mice with null mutation in the gene encoding MBL-Awere generated using
the traditional backcrossing method from MBL-A and MBL-C double-KO
breeders generated on a B6 background as described by Shi et al. (23) and
kindly provided by Drs. Jensenius and Thiel (Aarhus, Denmark). Offspring
of the first-generation backcross matings were genotyped by PCR for
MBL-A mutation and then bred back to the same pure strain, thus diluting
the contribution of the original genetic background by 50% for each
backcross generation. This process was repeated for seven generations, and
the MBL-A2/2 animals used in our experiments were .99% congenic on
the CBA/J genome.
Matings
The mating combinations included (female 3 male): CBA/J (H-2k) 3
BALB/c (H-2d) or CBA/J 3 DBA/2 (H-2d). The latter two combinations
both involve minor and major loci allogeneic disparities between males
and females. The male strains are MHC identical (H-2d) with disparity in
only minor loci. The CBA/J 3 BALB/c is a non–abortion-prone control
mating combination, whereas CBA/J 3 DBA/2 crosses yield abortion-
prone pregnancies (7).
FIGURE 1. Detection of C1q, MBL-A, and MBL-C on murine im-
plantation sites. Sections of tissue collected from CBA/J 3 DBA/2 and
CBA/J 3 BALB/c mating combinations at day 6.5 of pregnancy were
examined for the presence of C1q, MBL-A, and MBL-C by immuno-
fluorescence using specific rat mAbs revealed by goat anti-rat IgG labeled
with Alexa Fluor 488. Note the selective localization of MBL-A on the
implantation sites of CBA/J 3 DBA/2, whereas C1q is present on sections
from both mating combinations. Original magnification 3200.
FIGURE 2. Analysis of murine decidua for the presence of C1r, C4, C3,
and C9. Implantation sites were obtained from CBA/J mice mated to either
DBA/2 or BALB/c male mice at day 6.5 of pregnancy and examined for
the localization of the C components by immunofluorescence. Note the
positive staining for C4, C3, and C9 in the absence of C1r in CBA/J 3
DBA/2, whereas all these C components were undetectable in CBA/J 3
BALB/c mating combination. Original magnification 3200.
The Journal of Immunology 5603
 by guest on February 2, 2017
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
The mice were mated following details in a published procedure (24),
and pregnancies were dated from day 0.5 post coitum, the morning of
detection of a vaginal plug. The animals were euthanized on 3.5–14 ges-
tation days, and the resorbed fetuses were identified by their small size and
necrotic or hemorrhagic appearance compared with normal embryos.
Pregnant mice were randomly included in each experimental group, and
the results are presented as percentage of fetal loss calculated using the
formula %R = Re (Re + F), where R represents percentage of resorptions
as referred to total number of effective implantation sites, Re the number
of resorbed embryos, and F the number of viable embryos (25). The ex-
perimental procedures were performed in accordance with the rules
enforced by the French National Institutes of Health and Medical Re-
search, Universite´ Paris Sud, and Universite´ Paris Diderot and in com-
pliance with the European (86/609/EEC) and French laws.
Immunofluorescence analysis
Frozen sections (6 mm) of implantation sites from 10- to 11-wk-old mice
were examined for tissue deposition of C components. MBL-A, MBL-C,
C1q, and C4 were detected using rat mAbs (clones 8G6, 14D12, 7H8, and
16D2, respectively; Hycult Biotech, Uden, the Netherlands) followed by
Alexa Fluor 488–labeled goat anti-rat IgG (Jackson Immunoresearch, West
Grove, PA). Rabbit polyclonal Abs to human C1r cross-reacting with
mouse C1r (Sigma, Italy) and to mouse C9 (kindly provided by Prof. M.
Daha, Leiden, The Netherlands) were used to reveal deposition of C1r and
C9 using FITC-labeled goat anti-rabbit IgG (Jackson Immunoresearch) as
secondary Ab. C3 deposits were detected using FITC-conjugated goat
F(ab9)2 fragment to mouse C3 (Cappel UK) as previously described (26).
All Abs were incubated at room temperature for 1 h to a final concentration
of 5 mg/ml. The slides were examined using a DM2000 fluorescence mi-
croscope (Leica, Germany).
Statistical analysis
Statistical analysis was performed using GraphPad Prism 5.0 for Windows.
The fetal resorption data were analyzed using theMann–WhitneyU test and
expressed as median and interquartile range for nonparametric variables.
The p values ,0.05 were considered statistically significant.
Results
Kinetic analysis of C deposition at embryo implantation site
Previous finding of C3 deposits at embryo–maternal interface by
Girardi and colleagues (9) did not clarify the initiator factors
responsible for the activation of the C cascade and the pathway
involved in this process. To address this issue, we analyzed
samples of implantation tissue collected at day 6.5 of pregnancy
from both CBA/J 3 DBA/2 and CBA/J 3 BALB/c mating
combinations for the presence of the early components of the
classical and lectin pathways. As shown in Fig. 1, staining of
implantation sites of DBA/2-mated CBA/J female mice showed
deposits of C1q and MBL-A, whereas MBL-C was undetectable
using an Ab that was previously reported to reveal the presence
of this complement component on cerebral ischemic areas (14).
The Abs were checked for their specificities by Western blot
analysis and their failure to react with sera from mice with se-
lective complement deficiencies. Unlike MBL-A, C1q was also
present in the implantation sites of BALB/c-mated CBA/J mice.
We then searched for evidence supporting C activation in the
implantation sites of DBA/2-mated CBA/J mice analyzing the
tissue for the presence of C components involved in the activa-
tion sequence, and we were able to detect C4, C3, and C9, but
not C1r (Fig. 2). Failure to observe C1r could not be attributed to
the use of an inappropriate Ab because this Ab revealed deposits
of C1r on the implantation sites in a mouse model of complement-
mediated pregnancy loss induced by an Ab to beta2-GPI (26)
(Supplemental Fig. 1).
A strong staining for MBL-A mainly localized on vascular
endothelium was already apparent on day 3.5 of pregnancy
compared with the negligible or mild expression of the other C
components (Fig. 3). Analysis of MBL-A distribution on the im-
plantation site collected in more advanced stage of pregnancy
showed colocalization of MBL-A and C1q previously reported to
be constitutively expressed by decidual endothelial cells (ECs)
and extravillous trophoblasts invading the decidua, suggesting that
complement activation exerts its effect on the decidual side
(Supplemental Fig. 2). Differences in the staining intensity of C
deposits were noticed in various implantation sites. To investigate
the contribution of local synthesis of MBL-A to initiate MBL-
mediated activation of the lectin pathway, we analyzed MBL-A
RNA expression in the implantation sites of DBA/2-mated CBA/J
mice by quantitative PCR following a procedure previously
reported in detail (24) and failed to detect any signal at different
days of gestation (data not shown).
FIGURE 3. Analysis of early implantation sites for
the deposition of C components. Implantation sites
were collected from DBA/2-mated CBA/J female mice
at day 3.5 of pregnancy and examined for the presence
of C components by immunofluorescence. Note the
marked staining for MBL-A compared with the mild
expression of the other C components. Arrows point to
microvessels that are the primary sites of MBL-A de-
position. Original magnification 3200.
FIGURE 4. Analysis of decidua from MBL-A+/+ and MBL-A2/2 for
complement deposition. Decidual tissues were collected from either MBL-A+/+
or MBL-A2/2 CBA/J mice mated to DBA/2 mice on day 14 of pregnancy and
analyzed for the localization of MBL-A, C3, and C9. Note the presence
of all three C components in MBL-A+/+ and their absence in MBL-A2/2
mice. Original magnification 3200.
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MBL-dependent activation of the lectin pathway induces
pregnancy loss in CBA/J 3 DBA/2 mating
Having found an early deposition of MBL-A in the implantation
sites of CBA/J mated to DBA/2 mice, we then investigated the
ability of MBL to activate the lectin pathway and to negatively
influence the pregnancy outcome. To this end, MBL-A2/2 mice,
generated on a CBA/J background, were mated to DBA/2 male
mice, and the implantation sites of pregnant mice at 14 d of
pregnancy were examined for the presence of C components. As
expected, MBL-A was undetectable in the MBL-A KO mice as
opposed to the strong signal visualized in wild-type mice (Fig. 4).
We also failed to reveal deposition of C3 and C9 in the MBL-A
deficient animal, suggesting that C was activated through the lectin
pathway in the CBA/J 3 DBA/2 mating. Evaluation of pregnancy
outcome in pregnant CBA/J showed that MBL-A deficiency was
associated with a significant decrease in the median value of fetal
resorption from 22 to 0% (Fig. 5). The involvement of the late C
components in MBL-mediated C activation was investigated
treating pregnant MBL-A+/+ mice with a neutralizing Ab to C5 that
prevented pregnancy loss to a median level 4-fold lower than that
observed in mice receiving an unrelated Ab (Fig. 6).
Inhibition of lectin pathway activation rescue pregnancy in
CBA/J 3 DBA/2 mating
The finding that MBL-A deficiency protected CBA/2 pregnant mice
from fetal resorption led us to consider the possibility that the
proabortive effect ofMBL-Amay be controlled by an inhibitor of its
functional activity. To this purpose, we used Polyman2, a poly-
mannosylated dendrimer (a tetravalent pseudotrimannoside dendron)
previously found to bindMBLwith high affinity and to reduceMBL-
mediated brain ischemic injury (14). Because a substantial amount
of MBL-A was already localized in the maternal implantation
site at day 3.5 of pregnancy, we decided to treat the animals with
Polyman2 administered four times (200 mg/mouse i.p. on alternate
day) starting on day 0.5. As shown in Fig. 7, the drug was effective
in preventing the fetal resorption rate that dropped from 29% in
the untreated mice to 0% in animals receiving Polyman2. In ad-
dition, we failed to detect deposition of MBL-A, C3, and C9 in
mice treated with the MBL inhibitor (Fig. 8).
Discussion
Activation of the lectin pathway has been implicated in tissue
damage associated with ischemia reperfusion of several organs and
tissues including myocardium, gastrointestinal tract, skeletal
muscles, and brain (27, 28). The results of this study indicate that
the lectin pathway activation is also involved in the adverse
pregnancy outcome observed in DBA/2-mated CBA/J.
Pregnancy loss in CBA/J 3 DBA/2 mating combination has
been shown to be Ab independent and to be mainly mediated by
macrophages and NK cells (29), although the contribution of
T cells cannot be excluded. A few years ago, Girardi and col-
leagues (9) identified the C system as an additional player in the
CBA/J 3 DBA/2 model contributing to the high rate of fetal
resorption and inducing dysregulation of angiogenic factors. A
surprising finding of this study was the strong staining of the
implantation site of DBA/2-mated CBA/J pregnant mice for
MBL seen as early as 3.5 d of pregnancy. MBL deposition was
followed by C3 observed at day 6.5 of pregnancy in agreement
with a similar observation of Girardi et al. (9), who also found
that C3 appeared at the same time as the proinflammatory cells
monocytes and polymorphonuclear leukocytes. Our own obser-
vation that cytokines involved in pregnancy loss including IFN-g,
TNF-a, and IL-10 are not expressed earlier than 6.5 d of preg-
nancy is consistent with this kinetic (30). Taken together, these
data suggest that C may be the initiator of the complex series of
events mediated by multiple pathogenic factors leading to adverse
pregnancy outcome in this murine mating combination. Although
this issue was not addressed specifically in this work, the pos-
sibility that C acts upstream of the proinflammatory markers is
supported by the marked decrease in TNF-a level in a model of
anti-phospholipid syndrome established in C5-deficient mice
(31) and in rats treated with a neutralizing Ab to C5 undergoing
experimental arthritis (18). Despite the early deposition of MBL-A,
we believe that C activation triggered by this C component does
not affect implantation because the total number of fetuses in-
cluding both resorbed and live fetuses in MBL+/+ mice is within
the range obtained in MBL-A2/2 mice. Both C1q and MBL-Awere
detected at the implantation site of DBA/2-mated CBA/J mice with
the only difference that, unlike MBL-A, C1q was also present in
CBA/J mated to BALB/c male mice. The persistent localization
of C1q in different mating combinations was not surprising be-
cause we have previously found that C1q is constitutively expressed
by decidual ECs and extravillous trophoblasts, and is used to pro-
mote vascular remodeling and trophoblast migration (32, 33). This
might explain why C1q-deficient mice, at variance with CBA/J
mated with DBA/2, show hypertension during pregnancy. Con-
versely, the finding that deposits of MBL-A were restricted to the
abortion-prone CBA/J mice suggests that this C component may
be implicated in the pregnancy loss. Immunofluorescence analysis
of CBA/J decidua for deposition of MBL-A and MBL-C, the murine
FIGURE 6. Effect of anti-C5 Ab on fetal loss. DBA/2 females mated
with CBA/J males received six i.p. injections of either anti-C5 or unrelated
Abs (100 mg/400 ml sterile saline) on alternate days starting from the day
of vaginal plug detection. Six to 10 mice were in the experimental groups
and sacrificed on day 14 of pregnancy. The total number of implantation
versus resorptions in the anti-C5–treated mice was 39 versus 6 and in the
unrelated Ab treated group was 49 versus 17. The percentages of fetal loss
observed in the two groups of mice is presented as median (horizontal
bars) 6 interquartile range. *p = 0.040.
FIGURE 5. Deficiency of MBL-A prevents fetal loss in CBA/J 3 DBA/2
matings. MBL-A+/+ and MBL-A2/2 CBA/J female mice were mated to
MBL-A+/+DBA/2 male mice. Seven to 13 pregnant mice were included in
the experimental groups. The total number of implantation versus re-
sorptions in MBL-A2/2 mice was 53 versus 3 and in MBL-A+/+ mice was
81 versus 9. Animals were euthanized on day 14 of pregnancy, and the
number of resorbed and viable fetuses was counted. The results of per-
centage of fetal loss are presented as median (horizontal bars) 6 inter-
quartile range. *p = 0.002.
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counterpart of human MBL (34, 35), revealed tissue localization of
MBL-A in the absence of detectable MBL-C. This is surprising be-
cause MBL-C circulates in the blood of CBA/J mice at higher levels
than MBL-A and can more likely interact with ECs, which repre-
sent the primary target of this activator of the lectin pathway (36).
Moreover, both molecules have been detected on tissues under-
going ischemia-reperfusion injury (14, 37) and on the aortic root
in a mouse model of vasculitis (38). A possible explanation for the
selective binding of MBL-A is that ECs provide preferential
binding site for this C component. Hansen and colleagues (34)
observed a marked difference in the carbohydrate specificity of
murine MBL-A and MBL-C, and suggested that such a difference
may result in preferential binding to different infectious agents.
Whether this is also true for ECs from different sources remains
to be established. The liver is the main source of MBL-A and
MBL-C, suggesting that a substantial portion of MBL-A deposited
at the implantation site derives from the circulation (39). The
possibility that the protein may also be produced locally, as it is in
the kidney (39), can be ruled out by our failure to reveal MBL-A
RNA expression in the decidua.
The finding that DBA/2-mated MBL-A2/2 CBA/J mice showed
a marked reduction in miscarriage rates compared with MBL-A+/+
mice supports a critical role of MBL-A in inducing adverse
pregnancy outcome in this mating combination. MBL-A was
shown by van der Pol et al. (40) to have a damaging effect in-
dependent of C activation in a rat model of renal ischemia injury.
This was not the case in the abortion-prone CBA/J mice because
deposition of MBL-A in decidual tissue was associated with that
of C3 and C9, suggesting activation of the lectin pathway. Failure
to detect C1r, despite the persistent presence of C1q, rules out the
involvement of the classical pathway of C activation, whereas the
presence of C3 is compatible with activation of the alternative
pathway. However, this pathway may only contribute to amplify
the activation process, although the failure to reveal deposition of
C3 and C9 in MBL-A2/2 mice clearly indicates that the lectin
pathway is the major driver of C activation.
The ability of neutralizing recombinant Ab anti-C5 to rescue
CBA/J mice from pregnancy loss clearly indicates that the terminal
components are involved in the lectin pathway-mediated fetal
resorption. The major role in causing fetal demise has been at-
tributed to C5a through the recruitment of monocytes and gran-
ulocytes (9), although the deposition of C9 suggests that the
terminal complex may also be involved. It is important to note
that, despite complement deposition, a proportion of embryos
were still alive at day 14 of pregnancy. Although we cannot ex-
clude that some of these embryos would have experienced fetal
growth retardation if pregnancy had progressed to term, we are not
stating that complement activation is solely responsible for the
fetal loss in CBA/J females mated to DBA/2 males. Other factors
including proinflammatory cytokines such as TNF-a and IFN-g,
macrophages, and NK cells may contribute to this pathologic
process (24). Moreover, the staining intensity of complement
deposits differs in various implantation sites and is likely depen-
dent on different expression of triggering factors and complement
regulatory proteins.
The data presented in this article that Polyman2 preventsMBL-A
binding to the decidua of DBA/2-mated CBA/J mice inhibiting C3
and C9 deposition and rescuing these mice from pregnancy loss
further support the important contribution of the lectin pathway of
C activation to the adverse pregnancy outcome observed in this
mating combination. These findings have important clinical and
therapeutic implications because CBA/J 3 DBA/2 mating has
been shown to be an animal model of human PE and represents an
invaluable tool to validate novel therapies for PE patients. Poly-
man2 is a tetravalent trimannoside dendron that interacts with
MBL and has distinct advantages as a therapeutic inhibitor of C
activation. Because of the oligomeric structure, Polyman2 offers
multiple binding sites to MBL, which circulates in blood at a
relatively low level and is therefore easy to neutralize. Moreover,
MBL acts at the initial step of C activation, and its inhibition
prevents release of activation products that may cause local
damage. Finally, the preparation of Polyman2 is less expensive
than the production of neutralizing mAbs and its repeated ad-
ministration in the course of pregnancy has not been associated
with adverse effects.
In conclusion, we have provided data indicating that C activation
through the lectin pathway at implantation site in DBA/2-mated
CBA/J mice represents an early event leading to fetal resorption
in this mating combination. We have also shown that MBL-A is
selectively deposited in the decidua of pregnant mice and that
MBL-A–deficient mice and animals treated with an inhibitor of
MBL-A are rescued from pregnancy loss.
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FIGURE 8. Analysis of complement deposition on the decidua of
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implantation sites collected at 14 d of pregnancy were examined for the
presence of MBL-A, C3, and C9. Note the total absence of these C
components in contrast with the strong staining observed in the decidua of
mice receiving PBS. Original magnification 3200.
FIGURE 7. Effect of Polyman2 on fetal loss. DBA/2 females that mated
with CBA/J males received four i.p. injections of either Polyman2 (200 mg/
400 ml PBS) or PBS alone on alternate days starting from the day of
vaginal plug detection. Four to seven mice were included in the experi-
mental groups and sacrificed on day 14 of pregnancy. The total number of
implantation versus resorptions in the Polyman2-treated mice was 23
versus 1 and in the PBS-treated group was 24 versus 7. The percentages of
fetal loss observed in the two groups of mice is presented as median
(horizontal bars) 6 interquartile range. *p = 0.002.
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